|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dempke WC, Suto T and Reck M: Targeted
therapies for non-small cell lung cancer. Lung Cancer. 67:257–274.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK,
Govindan R, et al: Non-small cell lung cancer. J Nal Compr Canc
Netw. 10:1236–1271. 2012.
|
|
4
|
Sequist LV, Joshi VA, Jänne PA, Muzikansky
A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE and
Lynch TJ: Response to treatment and survival of patients with
non-small cell lung cancer undergoing somatic EGFR mutation
testing. Oncologist. 12:90–98. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ji H, Li D, Chen L, Shimamura T, Kobayashi
S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, et al:
The impact of human EGFR kinase domain mutations on lung
tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Cancer Cell. 9:485–495. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petrelli F, Borgonovo K, Cabiddu M and
Barni S: Efficacy of EGFR tyrosine kinase inhibitors in patients
with EGFR-mutated non-small-cell lung cancer: A meta-analysis of 13
randomized trials. Clin Lung Cancer. 13:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nguyen KS, Kobayashi S and Costa DB:
Acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors in non-small-cell lung cancers dependent on the
epidermal growth factor receptor pathway. Clin Lung Cancer.
10:281–289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seto T, Kato T, Nishio M, Goto K, Atagi S,
Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al:
Erlotinib alone or with bevacizumab as first-line therapy in
patients with advanced non-squamous non-small-cell lung cancer
harbouring EGFR mutations (JO25567): An open-label, randomised,
multicentre, phase 2 study. Lancet Oncol. 15:1236–1244. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reck M, Popat S, Reinmuth N, De Ruysscher
D, Kerr KM and Peters S: ESMO guidelines working group: Metastatic
non-small-cell lung cancer (NSCLC): ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
25(Suppl 3): iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liao BC, Lin CC and Yang JC: Second and
third-generation epidermal growth factor receptor tyrosine kinase
inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol.
27:94–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park SJ, Kim HT, Lee DH, Kim KP, Kim SW,
Suh C and Lee JS: Efficacy of epidermal growth factor receptor
tyrosine kinase inhibitors for brain metastasis in non-small cell
lung cancer patients harboring either exon 19 or 21 mutation. Lung
Cancer. 77:556–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang J, Yu J, Sun X and Meng X: Epidermal
growth factor receptor tyrosine kinase inhibitors in the treatment
of central nerve system metastases from non-small cell lung cancer.
Cancer Lett. 351:6–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soffietti R, Trevisan E and Rudà R:
Targeted therapy in brain metastasis. Curr Opin Oncol. 24:679–686.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Besse B, Le Moulec S, Mazières J,
Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L,
Gervais R, et al: Bevacizumab in patients with nonsquamous
non-small cell lung cancer and asymptomatic, untreated brain
metastases (BRAIN): A nonrandomized, Phase II Study. Clin Cancer
Res. 21:1896–1903. 2015. View Article : Google Scholar : PubMed/NCBI
|
